Travere Therapeutics, Inc.
A biopharmaceutical company focused on developing and commercializing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is FDA-approved to slow kidney function decline in adults with a rare kidney disease called primary IgA nephropathy, and the company also sells Thiola and Thiola EC for the kidney stone condition cystinuria. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for the rare metabolic disorder classical HCU.
Granted 962.0K · Sold 686.0K
Granted 70.0K · Sold 112.9K
Granted 140.6K · Sold 67.6K
Granted 149.8K · Sold 59.9K
Granted 202.9K · Sold 129.7K
Granted 191.4K · Sold 78.1K
Granted 255.4K · Sold 189.3K
Granted 72.5K · Sold 48.0K
Granted 72.5K · Sold 48.0K
Granted 52.5K · Sold 31.3K
Granted 112.0K · Sold 87.5K
Granted 211.9K · Sold 199.7K
Granted 24.5K
Granted 24.5K
Granted 17.3K · Sold 13.0K
Granted 24.5K
Granted 24.5K
Granted 24.5K
Granted 5.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Dube Eric MCHIEF EXECUTIVE OFFICER, Director · 47 transactions | +175.9% | 432.9K | 962.0K | — | 686.0K |
| Aselage SteveDirector · 9 transactions | — | 347.7Kas of May 2022 | 70.0K | — | 112.9K |
| Heerma PeterCHIEF COMMERCIAL OFFICER · 33 transactions | +121.5% | 140.7K | 140.6K | — | 67.6K |
| Cline Christopher R.CHIEF FINANCIAL OFFICER · 37 transactions | — | 118.7K | 149.8K | — | 59.9K |
| Rote William E.Chief Research Officer · 34 transactions | +223.2% | 115.5K | 202.9K | — | 129.7K |
| Inrig JulaCHIEF MEDICAL OFFICER · 36 transactions | — | 112.8K | 191.4K | — | 78.1K |
| Reed Elizabeth EChief Legal Officer and GC · 54 transactions | +180.2% | 105.2K | 255.4K | — | 189.3K |
| Meckler Jeffrey ADirector · 9 transactions | +36.6% | 91.5K | 72.5K | — | 48.0K |
| Lyons Gary ADirector · 10 transactions | +66.2% | 61.5K | 72.5K | — | 48.0K |
| Coughlin TimothyDirector · 11 transactions | +60.7% | 56.3K | 52.5K | — | 31.3K |
| Baynes Roy D.Director · 24 transactions | +170.6% | 46.0K | 112.0K | — | 87.5K |
| Calvin SandraSVP, CHIEF ACCOUNTING OFFICER · 47 transactions | — | 42.4K | 211.9K | — | 199.7K |
| Orwin John ADirector · 5 transactions | +164.7% | 39.4K | 24.5K | — | — |
| Squarer RonDirector · 5 transactions | +164.7% | 39.4K | 24.5K | — | — |
| Clague LauraChief Financial Officer · 7 transactions | +13.9% | 35.7Kas of May 2022 | 17.3K | — | 13.0K |
| Poole SandraDirector · 5 transactions | +257.9% | 34.0K | 24.5K | — | — |
| Bruhn Suzanne LouiseDirector · 5 transactions | +297% | 32.8K | 24.5K | — | — |
| Williams Brinkley RuthDirector · 5 transactions | — | 29.8K | 24.5K | — | — |
| Brinkley Ruth WilliamsDirector · 1 transaction | — | 5.3Kas of Sep 2021 | 5.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.75M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.